Negative regulation of the tumor suppressor p53 gene by microRNAs

Bartel DP . (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281–297.

Bartel DP . (2009). MicroRNAs: target recognition and regulatory functions. Cell 136: 215–233.

Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE et al. (2007). p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 17: 1298–1307.

Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP et al. (1998). Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497–1501.

Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH et al. (2007). Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26: 745–752.

Chng WJ, Price-Troska T, Gonzalez-Paz N, Van Wier S, Jacobus S, Blood E et al. (2007). Clinical significance of TP53 mutation in myeloma. Leukemia 21: 582–584.

Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M et al. (2004). Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64: 1546–1558.

Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ . (2006). miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34: D140–144.

Hanahan D, Weinberg RA . (2000). The Hallmarks of Cancer. Cell 100: 57–70.

Harris SL, Levine AJ . (2005). The p53 pathway: positive and negative feedback loops. Oncogene 24: 2899–2908.

He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y et al. (2007). A microRNA component of the p53 tumour suppressor network. Nature 447: 1130–1134.

Hu W, Chan CS, Wu R, Zhang C, Sun Y, Song JS et al. (2010). Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol Cell 38: 689–699.

John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS . (2004). Human microRNA targets. PLoS Biol 2: e363.

Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A et al. (2005). RAS is regulated by the let-7 microRNA family. Cell 120: 635–647.

Kan T, Sato F, Ito T, Matsumura N, David S, Cheng Y et al. (2009). The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. Gastroenterology 136: 1689–1700.

Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ et al. (2005). Combinatorial microRNA target predictions. Nat Genet 37: 495.

Kruse J-P, Gu W . (2009). Modes of p53 Regulation. Cell 137: 609–622.

Le MTN, Teh C, Shyh-Chang N, Xie H, Zhou B, Korzh V et al. (2009). MicroRNA-125b is a novel negative regulator of p53. Genes & Dev 23: 862–876.

Lewis BP, Burge CB, Bartel DP . (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15–20.

Mayer B, Oberbauer R . (2003). Mitochondrial regulation of apoptosis. News Physiol Sci 18: 89–94.

Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM et al. (2006). A pattern-based method for the identification of microRNA binding sites and their corresponding heteroduplexes. Cell 126: 1203–1217.

Park SY, Lee JH, Ha M, Nam JW, Kim VN . (2009). miR-29 miRNAs activate p53 by targeting p85α and CDC42. Nat Struct Mol Biol 16: 23–29.

Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I et al. (2008). E2F1-regulated microRNAs impair TGFβ-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 13: 272–286.

Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D et al. (2008). MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 105: 12885–12890.

Prendergast NJ, Atkins MR, Schatte EC, Paulson DF, Walther PJ . (1996). p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma. J Urol 155: 1685–1692.

Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N et al. (2007). Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 26: 731–743.

Riley T, Sontag E, Chen P, Levine A . (2008). Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9: 402–412.

Suzuki S, Adachi A, Hiraiwa A, Ohashi M, Ishibashi M, Kiyono T . (1998). Cloning and characterization of human MCM7 promoter. Gene 216: 85–91.

Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A et al. (2007). Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6: 1586–1593.

Toledo F, Wahl GM . (2006). Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6: 909–923.

Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L et al. (2007). Restoration of p53 function leads to tumour regression in vivo. Nature 445: 661–665.

Voeller HJ, Sugars LY, Pretlow T, Gelmann EP . (1994). p53 oncogene mutations in human prostate cancer specimens. J Urol 151: 492–495.

Vogelstein B, Lane D, Levine AJ . (2000). Surfing the p53 network. Nature 408: 307–310.

Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R et al. (2006). A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 124: 1169–1181.

Vousden KH, Prives C . (2009). Blinded by the light: the growing complexity of p53. Cell 137: 413–431.

Wang XW, Zhan Q, Coursen JD, Khan MA, Kontny HU, Yu L et al. (1999). GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci USA 96: 3706–3711.

Xiong W, Wu X, Starnes S, Johnson SK, Haessler J, Wang S et al. (2008). An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 112: 4235–4246.

Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V et al. (2007). Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445: 656–660.

Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M et al. (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189–198.